NEW YORK (GenomeWeb News) - Invitrogen said today it will buy primary cell provider CellzDirect for around $57 million in cash in an effort to expand its cellular analysis business.
 
CellzDirect’s human hepatocyte-based cell products and services are used in drug testing, particularly for predicting the effect of compounds on enzymatic metabolism in the liver.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.